Black Titan Corp (NASDAQ:BTTC) Stock Short Interest Declines 66.4%

Black Titan Corp (NASDAQ:BTTC) was the recipient of a large drop in short interest in the month of October. As of October 30th, there was short interest totaling 104,106 shares, a drop of 66.4% from the October 15th total of 309,564 shares. Currently, 1.0% of the shares of the company are short sold. Based on an average daily trading volume, of 260,364 shares, the short-interest ratio is presently 0.4 days.

Black Titan Stock Performance

BTTC stock traded up $0.02 during trading hours on Friday, hitting $0.32. 46,920 shares of the stock were exchanged, compared to its average volume of 3,915,652. Black Titan has a 12 month low of $0.28 and a 12 month high of $10.05. The company has a current ratio of 4.40, a quick ratio of 4.62 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $3.46 million, a P/E ratio of -0.11 and a beta of 1.21. The company has a 50-day simple moving average of $0.42 and a two-hundred day simple moving average of $0.96.

Black Titan (NASDAQ:BTTC) last announced its earnings results on Friday, November 6th. The company reported ($0.10) earnings per share (EPS) for the quarter.

Black Titan Company Profile

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.